Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0311137 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Chongzhi Bai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, Shanxi Province Hospital of Traditional Chinese Medicine, Taiyuan, China. Hauptthemen laut MEDLINE: Human papillomavirus 16, Recombinant Fusion Proteins, Molecular Docking Simulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanxi Provincial Key Research and Development Project, Basic Research Project of Shanxi Province, National Outstanding Youth Science Fund Project of National Natural Science Foundation of China.
Abstract (Originalsprache)
Cervical cancer ranks as the third most prevalent malignancy in women worldwide. The persistence of Human papillomavirus (HPV) infection stands out as the foremost risk factor for cervical cancer development. Among the numerous HPV subtypes, HPV16 infection emerges as the primary pathogenic determinant of cervical cancer. To date, no specific drugs have been approved. In this study, we engineered two high-affinity fusion protein targeting HPV16 L1 protein based on the alpaca-derived single-domain antibody 2C12 previously obtained in our laboratory. These two fusion proteins exhibited potent neutralizing activity against HPV16 pseudovirus with IC50 values of 7.8 nM and 6.5 nM, respectively. Molecular docking analysis revealed that 2C12 formed ten pairs of hydrogen bonds with HPV16 L1, among which Arg39 and Thr100 established multiple pairs of hydrogen bonds with HPV16 L1, indicating their crucial roles in antigen-antibody binding process. These structural and biological findings underscore the effective binding capacity of these fusion proteins to HPV16, leading to reduced viral load and providing valuable insights into therapeutic antibody and vaccine development against HPV 16 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Central Laboratory, Shanxi Province Hospital of Traditional Chinese Medicine, Taiyuan, China.
- CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
- College of Veterinary Medicine, Shanxi Agricultural University, Taigu, Jinzhong, China.
- School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, China.
- School of Medicine, Zhongda Hospital, Southeast University, Nanjing, China.
ORCID-Profile: Chongzhi Bai
Förderung
- Shanxi Provincial Key Research and Development Project
- Basic Research Project of Shanxi Province
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Zitieren
APA
Bai, C., Wang, R., Yang, Q., Hao, J., Zhong, Q., Fan, R., & Han, P. (2024). Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16. PLOS ONE. https://doi.org/10.1371/journal.pone.0311137
Vancouver
Bai C, Wang R, Yang Q, Hao J, Zhong Q, Fan R, et al. Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16. PLOS ONE. 2024. doi:10.1371/journal.pone.0311137
BibTeX
@article{Bai2024,
author = {Bai, Chongzhi and Wang, Ruoyu and Yang, Qian and Hao, Jianqing and Zhong, Qiming and Fan, Ruiwen and Han, Pengcheng},
title = {Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0311137}
}
EUVIMED